Finally, a limitation of our study is that we did not identify with biomarkers participants with underlying Alzheimer’s disease and that we did not have availability of a direct measurement of EPO or ferritin in the brain. The gene discussed is EPO; the disease is early-onset autosomal dominant Alzheimer disease.